Fig. 5.

Immunogenicity profile of MTBV8. Two injections were administered on day 1, and day 29, respectively (4 weeks apart). (A) Production and changes of different immunoglobulins in response to MTBV8 injection; (B) B lymphocyte counts for each entity state after two injections; (C) CD4⁺ T-helper (TH) lymphocyte counts for each entity state after two injections; (D) CD8⁺ T-cytotoxic (Tc) lymphocyte counts for each entity state after two injections; (E) Changes in cytokine and interleukin concentrations after two injections; “D” in the built-in diagram represents the insertion point of the danger signal; (F) DC counts for each entity state after two injections.